EE389 Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting

Abstract

An estimated 1.57 million pulmonary nodules (PNs) are detected annually in the US, a number that is increasing with more imaging and screening programs.1 Amongst these PNs, approximately 80% are initially categorized as low to moderate risk2 where many delays in cancer diagnosis occur. Workup of PNs can be essential to early diagnosis and management of non-small cell lung cancer (NSCLC). In these scenarios, a blood-based auto-antibody (AAb) test may be utilized to up-classify risk of malignancy to better inform management and treatment decisions. This study aimed to estimate the budget impact of a AAb test from a US Medicare payer perspective.